Pelthos Therapeutics Inc.
PTHSPelthos Therapeutics Inc. in brief
Pelthos Therapeutics Inc. is a listed company in the Biotechnology industry, based in Durham, North Carolina, USA. Its market value was $65 M on 30 October 2026, which makes it the 20,347th largest listed company in the world and the 3,744th largest in the USA on this site. In the year to December 2025 it had sales of $17 M and a net loss of $43 M. It employs about 92 people. Its largest product and service lines by sales in 2025 were Net product revenues (96%) and License and collaboration revenues (4%). Its shares trade under the symbol PTHS (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI®, and XEGLYZE®.
The July 1, 2025 merger transaction between Channel Therapeutics Corporation and LNHC, Inc., discussed below, resulted in Pelthos Therapeutics Inc. initially having (i) a commercially marketable product, ZELSUVMI for the treatment of molluscum contagiosum, which was launched in July 2025 shortly after the Merger (as defined below); (ii) a manufacturing facility, equipment and know-how to produce the active pharmaceutical ingredient used in ZELSUVMI and the NITRICILTM technology platform; and (iii) clinical-stage assets which selectively target the sodium ion-channel known as “NaV1.7”, which has been genetically validated as a pain receptor in human physiology. In addition, during the fourth quarter of 2025 the Company acquired two additional FDA approved products to expand its commercial product portfolio.
From the company's annual report filed with the US SEC: read the report
Pelthos Therapeutics Inc. timeline
- 2022
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2024
- 🔔Initial public offering as Chromocell Therapeutics CorpFinal prospectus filed with the SEC on 20 February 2024; shares registered for exchange trading on 15 February 2024.
- ✎Renamed Channel Therapeutics CorpFormerly Chromocell Therapeutics Corp.
- 2025
- ✎Renamed Pelthos Therapeutics Inc.Formerly Channel Therapeutics Corp.
Events of Pelthos Therapeutics Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,617 (Oct 2026) · #3,748 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 3.9×
- Price / book
- 1.7×
- Free cash flow yield
- -34.9%
- Net margin
- -257.9%
- Operating margin
- -193.0%
- Return on equity
- -111.4%
- Liabilities / assets
- 70.2%
- R&D / revenue
- 7.3%
- Revenue per employee
- $183 K
- Profit per employee
- $-471 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $17M | — | $-32M | $-43M | -257.9% |
| Dec 2024 | — | — | $-8M | $-8M | — |
| Dec 2023 | — | — | $-7M | $-7M | — |
| Dec 2022 | — | — | $-2M | $-2M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-23M | $0M | $-23M | $-23.04 | — |
| Dec 2024 | $-6M | $0M | $-6M | $-14.27 | — |
| Dec 2023 | $-1M | — | — | $-5.78 | — |
| Dec 2022 | $-2M | — | — | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue $15M (+107.8% on a year earlier), net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Oct 30, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale · Directors or officers changed · Bylaws amended · Shareholder vote · Regulation FD disclosure
- Oct 1, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Aug 18, 2026DEF 14AProxy statement
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 13, 202610-Q/AQuarterly report (amended) · period to Mar 2026
- Aug 13, 20268-KCurrent reportRestatement
- May 28, 20268-KCurrent reportRegulation FD disclosure
- May 21, 20268-KCurrent reportAuditor change · Directors or officers changed
- May 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure
Official filings of Pelthos Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $17 M
- Operating income
- $-32 M
- Net income
- $-43 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $130 M
- Total liabilities
- $92 M
- Total equity
- $39 M
As of December-2025
Top 29 institutional investors in Pelthos Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Murchinson Ltd. | 311,019 | +6,717 (+2.21%) | 7.91% | $7 M | Nov 13, 2026 |
| 2 | Ikarian Capital, LLC | 256,598 | 0 (0.00%) | 6.53% | $5 M | Nov 16, 2026 |
| 3 | AIGH Capital Management LLC | 256,012 | -73,086 (-22.21%) | 6.51% | $5 M | Nov 2, 2026 |
| 4 | Boothbay Fund Management, LLC | 103,411 | +1,435 (+1.41%) | 2.63% | $2 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 95,316 | -1,818 (-1.87%) | 2.42% | $2 M | Nov 13, 2026 |
| 6 | Wexford Capital LP | 84,616 | +62,252 (+278.36%) | 2.15% | $2 M | Nov 13, 2026 |
| 7 | Diadema Partners LP | 80,760 | +55,987 (+226.00%) | 2.05% | $2 M | Nov 16, 2026 |
| 8 | Cantor Fitzgerald, L. P. | 48,124 | -28,122 (-36.88%) | 1.22% | $1 M | Nov 16, 2026 |
| 9 | Persistent Asset Partners Ltd | 20,228 | +14,221 (+236.74%) | 0.51% | $0 M | Nov 13, 2026 |
| 10 | Knott David M Jr | 17,644 | -4,429 (-20.07%) | 0.45% | $0 M | Nov 12, 2026 |
| 11 | Geode Capital Management, LLC | 16,575 | +1,925 (+13.14%) | 0.42% | $0 M | Nov 6, 2026 |
| 12 | Citadel Advisors LLC | 15,453 | +407 (+2.71%) | 0.39% | $0 M | Nov 16, 2026 |
| 13 | Ashford Capital Management Inc | 15,000 | New | 0.38% | $0 M | Nov 16, 2026 |
| 14 | 1492 Capital Management LLC | 14,577 | +4,197 (+40.43%) | 0.37% | $0 M | Nov 12, 2026 |
| 15 | J. Goldman & Co LP | 13,783 | -24,292 (-63.80%) | 0.35% | $0 M | Nov 16, 2026 |
| 16 | Pale Fire Capital SE | 12,919 | 0 (0.00%) | 0.33% | $0 M | Nov 13, 2026 |
| 17 | State Street Corp | 10,800 | +1,000 (+10.20%) | 0.27% | $0 M | Nov 12, 2026 |
| 18 | Vanguard Fiduciary Trust Co | 10,363 | +490 (+4.96%) | 0.26% | $0 M | Nov 13, 2026 |
| 19 | BlackRock, Inc. | 5,093 | -231 (-4.34%) | 0.13% | $0 M | Nov 13, 2026 |
| 20 | China Universal Asset Management Co., Ltd. | 2,360 | +200 (+9.26%) | 0.06% | $0 M | Oct 28, 2026 |
| 21 | Vanguard Global Advisers, LLC | 1,370 | New | 0.03% | $0 M | Nov 13, 2026 |
| 22 | UBS Group AG | 1,224 | -993 (-44.79%) | 0.03% | $0 M | Nov 10, 2026 |
| 23 | Nuveen, LLC | 326 | New | 0.01% | $0 M | Nov 10, 2026 |
| 24 | Tower Research Capital LLC (TRC) | 221 | +16 (+7.80%) | 0.01% | $0 M | Nov 16, 2026 |
| 25 | Federation des caisses Desjardins du Quebec | 60 | New | 0.00% | $0 M | Nov 16, 2026 |
Show all 29: investors 26 to 29
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Royal Bank Of Canada | 47 | +41 (+683.33%) | 0.00% | $0 M | Nov 16, 2026 |
| 27 | Farther Finance Advisors, LLC | 40 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 28 | Morgan Stanley | 6 | New | 0.00% | $0 M | Nov 13, 2026 |
| 29 | Parallel Advisors, LLC | 5 | New | 0.00% | $0 M | Nov 3, 2026 |
Mutual funds holding Pelthos Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 78,008 | $2 M | 2.0% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 16,128 | $0 M | 0.41% | <0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 7,464 | $0 M | 0.19% | <0.01% | +5.8% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 4,991 | $0 M | 0.13% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 2,052 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,972 | $0 M | 0.05% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 1,818 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 1,180 | $0 M | 0.03% | <0.01% | −44% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 333 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Pelthos Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Peter GreenleafDirector | Sell10b5-1 plan | -797 | $21.17 | $17 K | 23,087 | Form 4 |
| filed | Matthew PaulsDirector | Sell10b5-1 plan | -786 | $21.00 | $17 K | 13,578 | Form 4 |
| filed | Ezra M. FriedbergDirector | Sell10b5-1 plan | -558 | $20.72 | $12 K | 80,484 | Form 4 |
| filed | Matthew PaulsDirector | Sell10b5-1 plan | -692 | $26.00 | $18 K | 14,458 | Form 4 |
| filed | Peter GreenleafDirector | Sell10b5-1 plan | -712 | $26.00 | $19 K | 23,969 | Form 4 |
| filed | Ezra M. FriedbergDirector | Sell10b5-1 plan | -534 | $26.03 | $14 K | 81,066 | Form 4 |
| filed | Matthew PaulsDirector | Sell10b5-1 plan | -94 | $27.36 | $3 K | 14,364 | Form 4 |
| filed | Peter GreenleafDirector | Sell10b5-1 plan | -85 | $27.27 | $2 K | 23,884 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Pelthos Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split ; 1-for-9.09 reverse split
Trading halts
- 2026-10-30 13:34 UTC, code M, resumed 13:39 UTC
- 2026-03-23 15:08 UTC, code M, resumed 15:13 UTC
- 2025-07-11 16:30 UTC, code M, resumed 16:40 UTC
- 2025-07-10 13:40 UTC, code M, resumed 13:45 UTC
- 2025-07-08 13:36 UTC, code M, resumed 13:41 UTC
Fails to deliver
- : 1,773 shares at $16.54
- : 671 shares at $15.20
- : 2,653 shares at $17.00
- : 1,100 shares at $19.59
- : 1,032 shares at $18.70
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Pelthos Therapeutics Inc. scorecard#
Passes 3 of the 14 checks that could be worked out: strongest in valuation (2 of 5), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.7×Price to book 1.7× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median3.9×Price to sales 3.9× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-34.9%Free cash flow is -34.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-23.04 vs -14.27Diluted EPS -23.04 in fiscal 2025 against -14.27 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$43 MNet income -$43 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✗Operating margin above its peers' median-193.0%-193.0% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-239.5%-239.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.1×Current ratio 2.06 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-0.71Z-score -0.71 (distress zone) for fiscal 2025.
Shareholder returns0 of 2
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year237.5%Diluted shares up 237.5% in fiscal 2025.
- ✗Dividends and buybacks above 3% of the market value0.0%Dividends and buybacks were 0.0% of the market value.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Pelthos Therapeutics Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -193.0% | -60.5% | |
| Net margin | -257.9% | -68.9% | |
| Return on equity | -239.5% | -61.0% | |
| Free cash flow margin | -135.1% | -61.5% |
3of 6on the Piotroski tests of financial strength
- Net loss of $43 million, the 4th loss-making year in a row.
- Free cash flow was negative: -$23 million.
- The share count rose 237.5% in the year.
- Goodwill and intangibles ($64 million) exceed shareholders' equity ($39 million).
Pelthos Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 17—100% | 0—— | — | — | |
| Cost of revenue | 4.0—23.7% | 0—— | — | — | |
| Research and development | 1.2+4.2%7.3% | 1.2r1.2−54.3%— | 2.6+558%— | 0.4—— | |
| Selling, general and administrative | 42+564%253% | 6.4—— | — | — | |
| General and administrative | — | 4.1+50.1%— | 2.7+149%— | 1.1—— | |
| Operating expenses | — | 7.6+10.3%— | 6.9+196%— | 2.3—— | |
| Total costs and expenses | 49+550%293% | 7.6—— | — | — | |
| Operating income | −32—−193% | −7.6r−7.6—— | −6.9—— | −2.3—— | |
| Interest expense and finance costs | 3.0+283%17.9% | 0.8r0.6+154%— | 0.3r0.0+128%— | 0.1—— | |
| Other non-operating income (expense) | −18—−109% | −0.4r−0.4—— | −0.5—— | −0.1—— | |
| Income before tax | −51—−302% | −8.0—— | −7.4—— | −2.5—— | |
| Income tax | −7.4—−44.0% | 0—— | — | — | |
| Net income attributable to shareholders | −43—−258% | −8.0r−8.0—— | −7.4—— | −2.5—— | |
| Earnings per share, basic | -23.04—— | -14.27r-1.43—— | -5.78r5.78−202%— | 5.65—— | |
| Earnings per share, diluted | -23.04—— | -14.27r-1.43—— | -5.78—— | — | |
| Shares, weighted average (basic) | 1.9+237%— | 0.6r5.6−56.3%— | 1.3+193%— | 0.4—— | |
| Shares, weighted average (diluted) | 1.9+237%— | 0.6r5.6−56.3%— | 1.3—— | — | |
| Balance sheet | |||||
| Cash and cash equivalents | 18+3404%13.8% | 0.5r0.0+413%37.5% | 0.10.0%104% | 0.1—182% | |
| Receivables | 8.9—6.8% | 0—0.0% | — | — | |
| Inventory | 24—18.1% | 0—0.0% | — | — | |
| Other current assets | 3.0+2688%2.3% | 0.1—7.7% | — | — | |
| Current assets | 53+3801%41.0% | 1.4r1.4+1320%100% | 0.1+75.0%100% | 0.1—100% | |
| Property, plant and equipment | 9.6—7.4% | 0—0.0% | — | — | |
| Right-of-use (leased) assets | 3.3—2.5% | 0—0.0% | — | — | |
| Goodwill | 25—18.9% | 0—0.0% | — | — | |
| Other intangible assets | 39—30.3% | 0—0.0% | — | — | |
| Total assets | 130+9425%100% | 1.4r1.4+1320%100% | 0.1+75.0%100% | 0.1—100% | |
| Accounts payable | 3.0+57.4%2.3% | 1.9r1.9−58.9%139% | 4.6+54.3%4794% | 3.0—5436% | |
| Current liabilities | 26+537%19.9% | 4.1r4.1−37.6%298% | 6.5+73.9%6786% | 3.8—6830% | |
| Lease liabilities (non-current) | 2.8—2.1% | 0—0.0% | — | — | |
| Total liabilities | 92+2141%70.2% | 4.1r4.1−37.6%298% | 6.5+73.9%6786% | 3.8—6830% | |
| Retained earnings | −65—−49.7% | −21r−21—−1569% | −14—−14026% | −6.1—−11147% | |
| Shareholders' equity | 39—29.8% | −2.7r−2.7—−198% | −6.4r−6.4—−6686% | −3.7—−6730% | |
| Total liabilities and equity | 130+9425%100% | 1.4r1.4+1320%100% | 0.1+75.0%100% | 0.1—100% | |
| Shares outstanding | 3.2+430%— | 0.6r6.1−84.4%— | 3.9r3.9+252%— | 1.1—— | |
| Cash-flow statement | |||||
| Share-based compensation | 5.5+204%32.5% | 1.8r1.8+3.8%— | 1.7+1474%— | 0.1—— | |
| Cash from operating activities | −23—−135% | −5.8r−5.8—— | −1.0—— | −1.6—— | |
| Capital expenditure | −0.1—−0.6% | 0—— | — | — | |
| Cash from investing activities | −5.2—−31.2% | 0—— | — | — | |
| Debt repaid | −0.8—−5.0% | −0.2—— | — | — | |
| Shares issued | 0−100%0.0% | 6.0+2238%— | 0.3—— | — | |
| Shares bought back | 0—0.0% | −0.1—— | — | — | |
| Cash from financing activities | 45+630%270% | 6.2r6.2+507%— | 1.0−37.0%— | 1.6—— | |
| Report | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Revenue | 51—100% | 15+108%100% | 16—100% | 11—100% | 9.4r17*—100% | 7.4—100% | 0—— | 0—— | — | — | — | — | |
| Cost of revenue | 8.6—16.8% | 1.7−28.3%10.8% | 3.6—23.1% | 1.7—15.3% | 1.7*—17.8% | 2.3—31.3% | 0—— | 0—— | — | — | — | — | |
| Research and development | 2.2+91.3%4.2% | 1.0+603%6.6% | 0.6+16.5%3.8% | 0.2−4.1%1.7% | 0.4*+31.2%4.0% | 0.1−65.1%2.0% | 0.5r0.5+3875%— | 0.2r0.2−58.4%— | 0.3r0.3*—— | 0.4r0.4—— | 0.0—— | 0.5—— | |
| Selling, general and administrative | 87+260%170% | 19+2.5%122% | 28+919%177% | 21+1187%194% | 20r18*+1181%210% | 18r20+1025%248% | 2.7—— | 1.6—— | 1.5*—— | 1.6—— | — | — | |
| General and administrative | — | — | — | — | — | — | 1.1−8.2%— | 1.1+38.4%— | 1.0*—— | 1.2—— | 1.2—— | 0.8—— | |
| Operating expenses | — | — | — | — | — | 23+1011%307% | 3.2+83.1%— | 1.8−5.2%— | 1.8r1.8*—— | 2.0r2.0—— | 1.8—— | 1.9—— | |
| Total costs and expenses | 103—202% | 25+10.2%163% | 33+919%211% | 24+1208%220% | 21*—228% | 23—307% | 3.2—— | 1.8—— | — | — | — | — | |
| Operating income | −52—−102% | −9.7—−63.0% | −17—−111% | −13—−120% | −12*—−128% | −15—−207% | −3.2r−3.2—— | −1.8r−1.8—— | −1.8r−1.8*—— | −2.0r−2.0—— | −1.8—— | −1.9—— | |
| Interest expense and finance costs | 8.3+432%16.2% | 2.3+68.6%14.7% | 2.4+996%15.3% | 2.4+129470%21.6% | 1.3*—14.0% | 1.3+3351%18.2% | 0.2—— | 0.0—— | 0*—— | 0.0r0—— | 0*—— | 0r0.0—— | |
| Other non-operating income (expense) | −33—−64.1% | 1.8—11.7% | −6.1—−39.1% | −12r2.9—−110% | −17*—−177% | −1.3−479%−18.1% | −0.2r−0.2—— | −0.1r−0.1—— | −0.1r−0.1*—— | 0.4r0.4—— | −0.0—— | −0.6—— | |
| Income before tax | −85—−166% | −7.9—−51.3% | −23—−150% | −25r−10—−230% | −29*—−304% | −17—−226% | −3.4r−3.4—— | −2.0r−2.0—— | −1.9*—— | −1.7r−1.7—— | −1.8—— | −2.6—— | |
| Income tax | −6.9—−13.5% | 0—0.0% | 0—0.0% | 0—0.0% | −6.9*—−73.7% | −0.5—−6.3% | 0—— | 0—— | — | — | — | — | |
| Net income attributable to shareholders | −78—−152% | −7.9—−51.3% | −23—−150% | −25r−10—−230% | −22*—−231% | −16—−219% | −3.4r−3.4—— | −2.0r−2.0—— | −1.9r−1.9*—— | −1.7r−1.7—— | −1.8r−1.8—— | −2.6r−2.6—— | |
| Earnings per share, basic | — | -2.04—— | -6.62—— | -7.57r-3.09—— | — | -5.30—— | -5.29r-5.38—— | -3.21r-0.32—— | — | -2.93r-0.29—— | -3.07r-0.31—— | -0.55—— | |
| Earnings per share, diluted | — | -2.04—— | -6.62—— | -7.57r-3.09—— | — | -5.30—— | -5.29r-5.38—— | -3.21r-0.32—— | — | -2.93—— | -3.07—— | -0.55—— | |
| Shares, weighted average (basic) | 3.9+26.2%— | 3.9+26.2%— | 3.5+443%— | 3.3+440%— | — | 3.1r3.1+429%— | 0.7r0.6+12.9%— | 0.6r6.1−86.9%— | — | 0.6r5.8—— | 0.6r5.8—— | 4.7—— | |
| Shares, weighted average (diluted) | 3.9+26.2%— | 3.9+26.2%— | 3.5+443%— | 3.3+440%— | — | 3.1r3.1+429%— | 0.7r0.6+12.9%— | 0.6r6.1−86.9%— | — | 0.6—— | 0.6—— | 4.7—— | |
| Balance sheet | |||||||||||||
| Cash and cash equivalents | 18—13.7% | 18+24.6%13.7% | 24+40903%17.6% | 32+24309%22.0% | 18+3404%13.8% | 14+35056%11.2% | 0.1r0.1+46.0%7.2% | 0.1r0.0−96.6%14.4% | 0.5r0.0—37.5% | 0.0—1.9% | 0.0—1.6% | 3.8—94.3% | |
| Receivables | 13—10.4% | 13—10.4% | 14—10.5% | 12—8.0% | 8.9—6.8% | — | — | — | 0—0.0% | — | — | — | |
| Inventory | 21—16.7% | 21−10.9%16.7% | 21—15.6% | 23—16.1% | 24—18.1% | 24—19.1% | — | — | 0—0.0% | — | — | — | |
| Other current assets | 3.0—2.3% | 3.0+426%2.3% | 2.8—2.1% | 2.5—1.7% | 3.0+2688%2.3% | 0.6—0.5% | — | — | 0.1—7.7% | — | — | — | |
| Current assets | 56—43.5% | 56+12.7%43.5% | 63+7600%46.1% | 70+7561%48.0% | 53+3801%41.0% | 50+2225%39.4% | 0.8−68.4%100% | 0.9−77.4%100% | 1.4r1.4—100% | 2.1—100% | 2.6—100% | 4.0—100% | |
| Property, plant and equipment | 8.5—6.6% | 8.5−16.3%6.6% | 8.9—6.5% | 9.3—6.4% | 9.6—7.4% | 10—8.0% | — | — | 0—0.0% | — | — | — | |
| Right-of-use (leased) assets | 2.9—2.3% | 2.9−12.5%2.3% | 3.0—2.2% | 3.1—2.2% | 3.3—2.5% | 3.4—2.7% | — | — | 0—0.0% | — | — | — | |
| Goodwill | 25—19.2% | 25−19.4%19.2% | 25—18.0% | 25—17.0% | 25—18.9% | 31—24.2% | — | — | 0—0.0% | — | — | — | |
| Other intangible assets | 36—28.2% | 36+11.8%28.2% | 37—27.2% | 38—26.4% | 39—30.3% | 33—25.7% | — | — | 0—0.0% | — | — | — | |
| Total assets | 129—100% | 129+1.9%100% | 137+16593%100% | 145+15855%100% | 130+9425%100% | 126+5808%100% | 0.8−68.4%100% | 0.9−77.4%100% | 1.4r1.4—100% | 2.1—100% | 2.6—100% | 4.0—100% | |
| Accounts payable | 3.7—2.9% | 3.7−34.4%2.9% | 5.9+17.3%4.3% | 6.1+136%4.2% | 3.0+57.4%2.3% | 5.7+343%4.5% | 5.0+497%606% | 2.6+8.1%286% | 1.9r1.9—139% | 1.3—59.8% | 0.8—32.1% | 2.4—59.7% | |
| Current liabilities | 31—24.4% | 31+26.9%24.4% | 32+337%23.3% | 25+390%17.2% | 26+537%19.9% | 25+594%19.6% | 7.3+163%889% | 5.1+76.0%560% | 4.1r4.1—298% | 3.6—167% | 2.8—107% | 2.9—72.0% | |
| Lease liabilities (non-current) | 2.4—1.9% | 2.4—1.9% | 2.6—1.9% | 2.7—1.8% | 2.8—2.1% | — | — | — | 0—0.0% | — | — | — | |
| Total liabilities | 135—105% | 135+98.0%105% | 139+1798%101% | 126r110+2369%86.7% | 92+2141%70.2% | 68+1811%53.9% | 7.3+163%889% | 5.1+76.0%560% | 4.1r4.1—298% | 3.6—167% | 2.8—107% | 2.9—72.0% | |
| Retained earnings | −121—−94.1% | −121—−94.1% | −113—−82.5% | −90r−75—−61.8% | −65—−49.7% | −43—−34.1% | −27—−3268% | −23—−2573% | −21r−21—−1569% | −20—−914% | −18—−686% | −16—−399% | |
| Shareholders' equity | −6.2—−4.8% | −6.2−111%−4.8% | −1.5—−1.1% | 19r35—13.3% | 39—29.8% | 58r58—46.1% | −6.5r−6.5—−789% | −4.2r−4.2−471%−461% | −2.7r−2.7—−198% | −1.4r−1.4—−66.7% | −0.2r−0.2—−7.1% | 1.1r1.1—28.0% | |
| Total liabilities and equity | 129—100% | 129+1.9%100% | 137+16593%100% | 145+15855%100% | 130+9425%100% | 126+5808%100% | 0.8−68.4%100% | 0.9−77.4%100% | 1.4r1.4—100% | 2.1—100% | 2.6—100% | 4.0—100% | |
| Shares outstanding | 3.9—— | 3.9+26.0%— | 3.7+452%— | 3.4−45.5%— | 3.2+430%— | 3.1−46.9%— | 0.7−88.4%— | 6.2+7.2%— | 0.6r6.1—— | 5.8—— | 5.8—— | 5.8—— | |
| Cash-flow statement | |||||||||||||
| Share-based compensation | 8.4+99.2%16.4% | 1.9−30.9%12.6% | 2.8+601%17.7% | 1.9+293%17.5% | 1.8*+239%19.2% | 2.8+443%38.0% | 0.4−14.2%— | 0.5r0.5+66.1%— | 0.5r0.5*—— | 0.5r0.5*—— | 0.5*—— | 0.3—— | |
| Cash from operating activities | −32—−62.8% | −5.2—−33.5% | −7.7—−49.1% | −13—−120% | −6.3*—−66.6% | −15r−15*—−206% | −0.4r−0.4*—— | −0.6r−0.6—— | −0.7r−0.7*—— | −0.2r−0.2*—— | −3.0*—— | −2.0—— | |
| Capital expenditure | −0.4—−0.7% | −0.1*—−0.4% | −0.0*—−0.0% | −0.2—−1.8% | −0.1*—−1.1% | 0*—0.0% | 0*—— | 0—— | — | — | — | — | |
| Cash from investing activities | −8.3—−16.1% | −0.1*−102%−0.4% | −0.0*—−0.0% | −0.2—−1.8% | −8.0*—−85.2% | 2.8*—37.3% | 0*—— | 0—— | — | — | — | — | |
| Debt repaid | — | — | — | — | 0*—0.0% | — | — | — | — | — | — | — | |
| Shares issued | — | — | — | — | — | — | — | — | 0*—— | 0*—— | 0*—— | 6.0—— | |
| Cash from financing activities | 44+62.9%86.5% | −1.2*−104%−7.6% | 0*−100%0.0% | 28+10909%252% | 18*—192% | 27*—360% | 0.4*−76.4%— | 0.3−95.6%— | −0.1r−0.1*—— | −1.0r−1.0*—— | 1.6*—— | 5.7—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q/A | 10-Q | 10-Q | 10-Q | 10-Q/A | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Pelthos Therapeutics Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Net product revenues$16 M96%—
- License and collaboration revenues$1 M3.5%—
Business segments
- Commercial operations$16 M96%—
- Research and Development operations$1 M3.5%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Pelthos Therapeutics Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office2 subsidiaries | — |
| 🇦🇺 Australia | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Pelthos Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Financial statements withdrawn 1 · Auditor changed 2 · Change in control 1 · Acquisition or sale completed 2 · Directors and officers 8 · Material agreement 8 · New debt 6 · Unregistered share sale 5 · Shareholder rights changed 3 · Bylaws or fiscal year changed 3 · Shareholder vote 4 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officersMaterial agreementNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Financial statements withdrawn | 8-K | |
| Results announced | 8-K | |
| Auditor changedDirectors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Acquisition or sale completedResults announced | 8-K/A | |
| Results announced | 8-K | |
| Change in controlAcquisition or sale completedDirectors and officersMaterial agreementNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Auditor changedMaterial agreementUnregistered share saleShareholder vote | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officersMaterial agreementNew debtShareholder rights changedBylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2026 | $58 M | Private placement after listing | $50 to $250 million | 7 | equity, options | SEC |
| Nov 2025 | $18 M | Private placement after listing | $10 to $50 million | 8 | options | SEC |
| Jul 2025 | $50 M | Private placement after listing | $50 to $250 million | 13 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Pelthos Therapeutics Inc.#
1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $330 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Vice President of Clinical DevelopmentNatural Sciences Managers | 1 | $330 K |
Where: Freehold, NJ 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Chromocell Therapeutics Corporation
How Pelthos Therapeutics Inc. compares in Biotechnology
- Market cap$65 M · higher than 30% of 726
- Revenue$17 M · higher than 49% of 647
- Net margin-257.9% · higher than 22% of 408
- Price / sales3.9× · lower than 69% of 339
- Price / book1.7× · lower than 63% of 534
- FCF yield-34.9% · higher than 32% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Pelthos Therapeutics Inc.🇺🇸 | $65 M | — | -257.9% | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Pelthos Therapeutics Inc.? Verify and update this profile — free
Show Pelthos Therapeutics Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.